Reuters logo
BRIEF-Inventiva and Boehringer Ingelheim to develop new idiopathic pulmonary fibrosis treatments
September 5, 2017 / 6:35 AM / 3 months ago

BRIEF-Inventiva and Boehringer Ingelheim to develop new idiopathic pulmonary fibrosis treatments

Sept 5 (Reuters) - INVENTIVA SA:

* ANNOUNCES THE EXERCISE BY BOEHRINGER INGELHEIM OF ITS OPTION TO JOINTLY DEVELOP NEW TREATMENTS FOR IDIOPATHIC PULMONARY FIBROSIS

* THE EXERCISE OF THIS OPTION FOLLOWS THE VALIDATION OF A NEW TARGET FOR THE TREATMENT OF FIBROSIS

* THIS OPTION TRIGGERS THE PAYMENT OF 2.5 MILLION EUROS TO INVENTIVA

* UNDER THE TERMS OF THE AGREEMENT, CO WILL BE ABLE TO RECEIVE RESEARCH GRANTS AND MILESTONE PAYMENTS FOR UP TO € 170 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below